The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The FDA’s recent activities regarding Covid-19 vaccines stray far from the well-established standards of vaccine regulatory processes.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 ...

Both of those vaccines already have full FDA approval for individuals 12 and older, and are authorized for use in children as young as 6 months. The news came after Novavax, Inc. (NASDAQ ...

Novavax, Inc. (NASDAQ:NVAX)'s vaccine stands out as the only protein-based COVID-19 shot available in the U.S., offering an alternative to the mRNA-based vaccines from Pfizer and Moderna. Both of ...

The Novavax Covid-19 vaccine has had emergency use authorization since 2022 and an updated version was approved in August 2924. The brand name is Nuvaxovid. The FDA granted Pfizer-BioNTech full ...